Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Jan 12, 2021 3:36am
241 Views
Post# 32273713

RE:RE:RE:Phase 2 study Inquiry

RE:RE:RE:Phase 2 study Inquiry
Rumpl3StiltSkin wrote:
StevenBirch wrote: I think they have learned a lot since the first lockdown last spring and maybe most importantly is that there are other illnesses and medical emergencies that are a priority also. I would be very disappointed if they had to delay again for various reasons and I think that is just speculation at this point. 

Case in point, they are testing a treatment/vaccine for covid and we don't hear anything? So I wouldn't take silence as a delay rather just a lack of urgency by the company to keep us informed.


VentureGuy24 wrote: Are we enrolling and treating patients? Has covid wave 2 caused another delay? This company has been very silent on all fronts. I fear our trial just got extended again.

 



I'm expecting some great news out of TLT soon, maybe this month still. Something from Dr. Coombs. Some CR data from Phase 2. If they are both good then we may see that .50c number fall pretty damn quick.


 

Hey RSS... still happily & patiently waiting for in-vivo small animal results re: our compound's efficacy against BSL-3 SARS-CoV-2 (virus causing Covid-19)....my timeline puts results coming out by end of Q1, then off to human trials...."subject to suitable financing" per the NR.   Crossing my fingers that "suitable financing" comes in the form of a grant or a wealthy partner.  The preclinical evidence continues to grow re: the efficacy of PDT against various enveloped viruses, including the one causing Covid-19.

Based on the fact that our compound has demonstrated (preclinically) a superior form of DAMP-mediated immunogenic cell death (which augments its direct cytotoxic/anti-cancer effects), one can reasonably assume that our compound will have the clinical ability to unleash pathogen-associated molecular patterns (PAMPs), stimulating superior immunity against enveloped viruses (like SARS-CoV-2, Flu, Zika, etc).  Imo, the production of these PAMPs via treatment of viruses with TLD-1433/PDT could potentially replace a commonly used anti-viral vaccine production method, which uses a non-ionic detergent to solubilize the virions.  This latter method may lead to a less specific/effective anti-viral vaccine.

Now add to the above our compound's anti-Covid therapeutic potential : )...a little nasal/upper airway therapeutic spray or rinse for early or mild illness, & an inhaled version for more advanced or lower airway disease....potentially with or without PDT.  

My bad for being off topic ; ).  Best of luck Longs!

<< Previous
Bullboard Posts
Next >>